Familex Tablet (Famciclovir)

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Administer 250 mg of this medicine per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer 125 mg of this medicine per dose orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine per dose orally twice daily. Temporarily discontinue treatment at regular intervals every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment: Because the creatinine clearance of this medicine is reduced in patients with renal impairment, dose adjustment should be undertaken with caution. The dosage and administration for these patients are as follows. 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose twice daily 10～29 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59 125 mg per dose twice daily 10～29 125 mg per dose once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59 250 mg per dose twice daily 10～29 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients on hemodialysis, administration every 48 hours is preferable, taking the dialysis interval into account. Since 4 hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be used in certain patients. For example, patients who have had allergic reactions to this drug or its components, or those with genetic issues like lactose intolerance, lactose deficiency, or glucose-galactose malabsorption should not take this medication. Patients with impaired kidney function should be especially cautious when using this drug, and dose adjustments may be necessary. Common symptoms that may appear when taking this medication include headache, nausea, vomiting, abdominal pain, and diarrhea, and serious side effects such as thrombocytopenia or renal function abnormalities have been reported, albeit rarely. Skin rashes or itching may also occur, and if any unusual symptoms appear, immediate consultation with medical staff is necessary. This drug does not cure genital herpes, so it is important to avoid sexual contact and maintain safe sexual relationships even if symptoms are present during treatment. If recurrence symptoms appear, prompt treatment should be initiated. Symptoms such as dizziness, drowsiness, and confusion can occur, so caution is advised when driving or operating machinery. Patients with mildly impaired liver function do not require special dosage adjustments, but caution is needed for patients with severe liver dysfunction as safety has not been established. This medication may interact with other drugs, so if you are taking other medicines, be sure to inform your healthcare provider. Special caution is advised when used in conjunction with medications that affect renal excretion due to potential toxicity risks. Pregnant or breastfeeding women should consult with a doctor before administration as the safety of this drug has not been fully established. It is preferable not to use this medication in children under 18, as its safety and efficacy have not been adequately verified. Elderly patients generally do not require dosage adjustments, but adjustments should be made if kidney function is reduced. In case of an overdose, immediate medical attention is required for appropriate treatment, and hemodialysis may be beneficial. Store in a dry place at a temperature below 30 degrees Celsius, in a tightly closed container, and keep out of reach of children; do not store in other containers.

• headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

Store this medication in a tightly sealed container to prevent air or moisture from entering, and keep in a cool, dry place at a temperature below 30 degrees Celsius.

Appearance

White, round film-coated tablet

Package unit

For domestic use: 21 tablets (7 tablets/PTP × 3)